share_log

Regeneron Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Thompson Craig B.

SEC ·  Jan 7 05:13

Summary by Futu AI

On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
On January 2, 2025, Thompson Craig B., associated with Regeneron Pharmaceuticals, acquired 166 shares of Common Stock at $0 per share through a grant or award. This transaction was reported as completed.Following the acquisition, Thompson Craig B.'s direct ownership of Regeneron's Common Stock increased to 620 shares. The shares were acquired under a 'Direct' ownership form, indicating personal ownership rather than through an intermediary or related entity.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated